The Role of Angiopoietin, Tie-2, and Vascular Endothelial Growth Factor (VEGF) in Sepsis-Induced Multiple Organ Dysfunction Syndrome (MODS)
The Role of Angiopoietin, Angiopoietin Receptor Tie-2, and Vascular Endothelial Growth Factor in Sepsis-Induced Multi-Organ Dysfunction Syndrome
1 other identifier
observational
120
1 country
1
Brief Summary
This study is designated to determine serum concentrations of inflammatory mediators Ang-1, Ang-2, Ang-1/Ang-2 ratio, and Tie-2 in patients with sepsis-induced MODS and to investigate the association among increased permeability, inflammatory mediators, and these serum mediators in development of organ failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2008
CompletedFirst Submitted
Initial submission to the registry
May 25, 2009
CompletedFirst Posted
Study publicly available on registry
May 27, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2010
CompletedMay 27, 2009
May 1, 2009
2.1 years
May 25, 2009
May 26, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
mortality
in hospital mortality
Secondary Outcomes (1)
organ failure
In ICU stay
Study Arms (2)
survivor
survivors of patients
fatalities
non-survivors of patients
Eligibility Criteria
patients admitted to ICU due to sepsis
You may qualify if:
- Patients must have known origin of infection plus at least 2 of the following criteria of systemic inflammatory response syndrome:
- fever \> 38C or hypothermia \< 36C;
- heart rate \> 90 beats/ minute;
- respiratory rate \> 20 breaths/minute or PaCO2\< 32 mmHg or mechanical ventilation for an acute process;
- WBC count \> 12x109/L or \< 4x109/L or \> 10% immature neutrophils.
You may not qualify if:
- Age less than 18 years,
- Pregnant,
- Inability to provide informed, written consent,
- Patients with urologic trauma resulting in frank hematuria, urinary infection, or existing chronic renal disease (serum creatinine level \> 2.0 mg/dL),
- Patients receiving nephrotoxic drugs, admitted to the hospital following a surgical procedure, or remaining in the ICU for \< 72 hours will be also excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chang Gung Memorial Hospital
Taoyuan District, 333, Taiwan
Related Publications (1)
Lin SM, Wang YM, Lin HC, Lee KY, Huang CD, Liu CY, Wang CH, Kuo HP. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med. 2008 Mar;36(3):683-9. doi: 10.1097/CCM.0B013E31816537D8.
PMID: 18431261BACKGROUND
Biospecimen
whole blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shu-Min Lin, MD
Chang Gung Memorial Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 25, 2009
First Posted
May 27, 2009
Study Start
July 1, 2008
Primary Completion
August 1, 2010
Study Completion
August 1, 2010
Last Updated
May 27, 2009
Record last verified: 2009-05